Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Feasibility Study of the SENSE Device

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03827720
Recruitment Status : Not yet recruiting
First Posted : February 1, 2019
Last Update Posted : February 1, 2019
Sponsor:
Information provided by (Responsible Party):
Sense Diagnostics, LLC

Brief Summary:
A single site, study of the SENSE device in up to 20 study subjects, (five healthy controls and five each with ICH, AIS with LVO and AIS without LVO) in whom SENSE can be applied within 24 hours of stroke symptom onset.

Condition or disease Intervention/treatment Phase
Hemorrhagic Stroke Ischemic Stroke Device: SENSE Device Not Applicable

Detailed Description:

This will be a single site, study of the SENSE device in up to 20 study subjects, (five healthy controls and five each with ICH, AIS with LVO and AIS without LVO) in whom SENSE can be applied within 24 hours of stroke symptom onset. LVO will be defined as occlusion of the internal carotid artery (ICA) or middle cerebral artery (M1 or M2). All images in stroke patients will be reviewed by an independent neuroradiologist and final diagnoses ascertained by an independent neurologist. The treating clinicians will be blinded to the data collection and SENSE device scanning as described below.

A history and physical examination will be performed by the treating physician, and routine evaluations (including a diagnostic head CT/CT angiogram or MR/MR angiogram). All eligible subjects must have the diagnostic head CT/MR scan and clinical diagnosis of a stroke (ICH, AIS with LVO or AIS without LVO) performed within 24 hours of symptom onset.

Eligible subjects or legally authorized representatives will be approached for enrollment. Prior to obtaining informed consent, concurrence of patients' eligibility for this study and an assertion that the patient is clinically stable will be obtained from the treating team and its attending physician prior to obtaining informed consent. After obtaining informed consent to participate in the study, the SENSE device will be placed on the subject and monitoring will proceed over 45 minutes. A research coordinator will be present at the bedside for the 45 minutes of SENSE monitoring.

After enrollment, routine clinical management will ensue in the emergency department (ED), hospital ward or intensive care unit (ICU) as appropriate. A standard of care head CT with or without CT angiography or MR with or without angiography performed prior to diagnosis will be collected and analyzed. All enrolled AIS subjects must have a CT or MR angiography performed within 24 hours to establish absence or presence of LVO. Study procedures shall not delay, detract or interfere with medically necessary care or with planned treatments.

The SENSE device will be placed on the subject's head, and two small ink dots will be marked on the head corresponding to a known location on the device to allow for the device to be removed and replaced consistently throughout the 45 minutes of testing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The Sensor Evaluation of Neurologic Status in Emergencies (SENSE) device (Sense Diagnostics LLC; Cincinnati, OH) is a non-invasive radiofrequency (RF) sensor that detects and monitors intracranial hemorrhage (ICH).
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Early Feasibility Study of the SENSE Device in Healthy Volunteers and Patients With Hemorrhagic Stroke, Ischemic Stroke With Large Vessel Occlusion, and Ischemic Stroke Without Large Vessel Occlusion
Estimated Study Start Date : March 2019
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : December 2019

Arm Intervention/treatment
Experimental: Control
Healthy volunteers monitored with Sense Device
Device: SENSE Device
Non-invasive radiofrequency (RF) sensor
Other Name: CT Scan

Experimental: Intracranial Hemorrhage
Intracranial hemorrhage patients monitored with Sense Device
Device: SENSE Device
Non-invasive radiofrequency (RF) sensor
Other Name: CT Scan

Experimental: Acute Ischemic Stroke with LOV
Acute Ischemic Stroke patients that have large vessel occlusion monitored with SENSE Device
Device: SENSE Device
Non-invasive radiofrequency (RF) sensor
Other Name: CT Scan

Experimental: AIS without LOV
Ischemic Stroke patients that do not have large vessel occlusion monitored with SENSE device
Device: SENSE Device
Non-invasive radiofrequency (RF) sensor
Other Name: CT Scan




Primary Outcome Measures :
  1. Correlation of SENSE signal with CT scan for stroke severity (location), hemorrhage volume (ABC method) and AIS LOV status (presence and location) [ Time Frame: 45 minutes ]
    The change in received power (PR) measured by the SENSE device will be calculated and the accuracy of the SENSE algorithm will be tested for the SENSE measurement that correspond with diagnostic CT scan for stroke severity, hemorrhage volume and in the case of AIS, presence or absence of LVO..


Secondary Outcome Measures :
  1. Number of participants that completed the 45 mins monitoring session with the Sense Device successfully through confirmation that all planned data has been collected. [ Time Frame: 45 minutes ]
    The ability to process collected data in a manner that allows application and use of the SENSE device in a clinical environment through assessment of all participants that have complete SENSE Device data.

  2. Number of participants with adverse events (AE), unanticipated adverse device effects (UADE) and serious adverse events (SAE) as defined in the protocol. [ Time Frame: 7 days ]
    Preliminary estimate of the safety of the device when used in a clinical setting through tabulation and summary of AEs, UADEs and SAEs.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female patients age 22 years and older
  2. Established diagnosis of AIS (with or without LVO) or ICH within 24 hours of symptom onset
  3. Signed written informed consent by study subject or, if subject is unable, by subject's next of kin or legal guardian
  4. Willingness and ability to comply with 45 minutes of SENSE monitoring per study procedures
  5. Attending (Treating) physician has indicated that the patient is stable and has approved the patient's participation in the study

Exclusion Criteria:

  1. Female patients who are pregnant or lactating
  2. Patients with a known seizure disorder or those who have a seizure at stroke onset
  3. Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for the SENSE device monitoring or study participation or may confound the outcome of the study
  4. Intraventricular hemorrhage requiring emergent ventriculostomy placement on the eligibility CT or MRI
  5. Secondary cause of ICH suspected (e.g., arteriovenous malformation, cavernoma, aneurysm, hemorrhagic transformation ischemic stroke, venous sinus thrombosis, trauma)
  6. Pontine or infratentorial location of ICH
  7. In AIS patients, treatment with intravenous alteplase and/or mechanical thrombectomy prior to the initiation of 45 minutes of SENSE monitoring
  8. Current participation in an interventional clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03827720


Contacts
Layout table for location contacts
Contact: Susan Reilly, RN 513-862-2877 susan_reilly2@trihealth.com
Contact: Andrew Ringer, MD 513-221-1100

Locations
Layout table for location information
United States, Ohio
TriHealth Hatton Research Institute - Good Samaritan Hospital
Cincinnati, Ohio, United States, 45212
Contact: Susan Reilly, RN    513-862-2877      
Principal Investigator: Andrew Ringer, MD         
Sponsors and Collaborators
Sense Diagnostics, LLC
Investigators
Layout table for investigator information
Principal Investigator: Andrew Ringer, MD TriHealth Hatton Research Institute - Good Samaritan Hospital
Layout table for additonal information
Responsible Party: Sense Diagnostics, LLC
ClinicalTrials.gov Identifier: NCT03827720    
Other Study ID Numbers: SENSE-002
First Posted: February 1, 2019    Key Record Dates
Last Update Posted: February 1, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes